ClinicalTrials.gg
RecruitingNCT06341413Updated Jul 15, 2026

Sleep and Emotion Processing in Adolescent Post-traumatic Stress Disorder

An interventional study of SmartSleep device in Post Traumatic Stress Disorder, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Stress Disorders, Post-Traumatic by University of Wisconsin, Madison — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Wisconsin, Madison.

Planned enrollment
3rd of 15
180 · median 70
Started
2024
with 1 other
No phase
10 of 15
3 open now
Registered
11th of 15
by date

Among the 15 studies in Stress Disorders, Post-Traumatic by University of Wisconsin, Madison, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 10 with no phase, and was the 11th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 15 studies in Stress Disorders, Post-Traumatic by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 14 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Stress Disorders, Post-Traumatic by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

The goal of this clinical trial is to characterize the role of sleep, emotion processing, and daily affect in post-traumatic stress disorder (PTSD) and whether improving sleep quality using slow wave activity enhancement will impact next-day affect in youth.

Participants will attend 4 study visits:

  • A clinical and trauma assessment visit
  • A testing day that may include cognitive testing, surveys, and an MRI.
  • An overnight sleep study following one week of at-home sleep recordings with the device in the sham condition
  • An overnight sleep study following one week of at-home sleep recordings with the device in the sleep enhancement condition
Read the detailed description

In this study, researchers aim to characterize sleep and explore its relationship to emotion processing and daily affect in 165 youth spilt into 3 groups. Researchers will use advanced sleep assessment methodologies including: (1) high-density EEG (256 channels) in the laboratory to explore the regional distribution of sleep before and after an emotional learning task and; (2) a sleep-wearable EEG recording headband, SmartSleep, to record sleep longitudinally at home. Using SmartSleep's sleep enhancement algorithms, researchers will determine whether the deepest sleep, slow-wave activity (SWA) of non-rapid eye-movement (NREM) sleep, can be reliably increased in all youth.

03

Conditions studied

  • Post Traumatic Stress Disorder
04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

All participants must meet all of the following criteria:

  • Aged 14-18 years old, inclusive
  • Must agree to inform the investigators within 48 hours of any emergent medical conditions and procedures
  • Able to lie still on their back for up to 1 hour
  • Must not be pregnant
  • Must agree not to participate in any other interventional clinical trials during the duration of the study
  • Must be willing to comply with all study procedures
  • Agree to have study visits video and/or audio recorded, including consent visit, clinical assessments (for staff training) and in-laboratory sleep visits (recording deleted within one month of study visit).
  • A primary parent or guardian is willing participate in the study and to provide
  • Are fluent in or predominantly speaking and reading in English

In addition, PTSD and TEC youth must satisfy the following criteria:

- Must have a history of at least one traumatic event of any type, as defined by the . This may include exposure to physical or sexual abuse, witnessing violence against loved ones or friends, traumatic accidents, natural disasters, death of a close family member etc.

Additional criteria for PTSD youth:

- At baseline, meet threshold for DSM-5 criteria for current severe PTSD, as determined by the semi-structured clinical interview (KSADS).

Exclusion Criteria:

  • Caregiver or adolescent is unwilling or unable to give adequate informed consent.
  • Are likely, in the investigator's opinion and via observation during the screening and clinical assessment period, to be re-exposed to their index trauma or other significant trauma, lack social support, or lack a stable living situation during study participation.
  • Any finding(s), based on the screening process, that the PI feels would make the study unsuitable for the participant.
  • Participation in the last 30 days in a clinical study involving an drug
  • MRI
  • Claustrophobia or inability lie still in the scanner after practice MRI sessions.
  • Any participant presenting current serious suicide risk, as determined through the KSADS, responses to C-SSRS, and/or clinical judgment of the investigator, will be excluded; however, history of suicide attempts is not an exclusion. Would present a serious risk to others as established through clinical interview and contact with treating physician.
  • Neurodevelopmental disorders such as autism spectrum disorder
  • Intellectual Disability (IQ less than 70, per self-report)
  • Currently impaired by any medical condition that would prevent study participation
  • Traumatic brain injury with ongoing symptoms, including headache, visual disturbances, and/or impairments in concentration.
  • Neurological disorder(s) such as seizures, epilepsy, or brain tumors (Tourette's disorder, as diagnosed in the KSADS, is not exclusionary for TEC/PTSD youth)
  • Current use of medications or other drugs (i.e., alcohol) in a manner that may interfere with sleep.
  • Possible pregnancy

Exclusions for Typically developing youth:

  • No history of or current psychopathology, as defined in the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), with exception of past specific phobia and past, resolved episodes of depressive or anxiety disorders. Provided that:

    • The episode is not current (i.e. does not meet current criteria as assessed by the KSADS),
    • The participant is not currently receiving psychiatric treatment (medication or psychotherapy) for mood/anxiety, and
    • There is no current serious suicide risk (per KSADS/C-SSRS).
  • Current diagnosis of a sleep disorder (self-report).
  • Any history of any traumatic experience as defined by the DSM-V, including IPV exposure, neglect, or emotional abuse etc.

PTSD Youth:

- Current diagnosis of or history of psychotic disorder, bipolar disorder, or autism spectrum disorder diagnosed by the KSADS interview. No other co-morbid disorders are exclusionary.

TEC Youth:

- A current diagnosis of PTSD or a current diagnosis of or history of psychotic disorder, bipolar disorder, or autism spectrum disorder diagnosed by the KSADS interview.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Stimulation mode first

    During one week, the SmartSleep device will be set to stimulation mode.

    Device: SmartSleep device

  • Sham comparator
    Sham mode first

    During one week, the SmartSleep device will be set to sham.

    Device: SmartSleep device

Interventions

  • DeviceSmartSleep device

    Device worn during sleep

06

What researchers measure

Primary outcomes

  1. Change in Emotional Regulation - arousal

    Participants will view 140 target stimuli - 70 negative and 70 neutral- in pseudorandom order. The Self-Assessment Manikin Scale for Arousal 142 (SAM) appears after the target image and participants are asked to rate degree of emotional arousal experienced while processing the picture by pressing one of nine response buttons (ranging from 1 = very low to 9 = very high).

    Time frame: First overnight session to second overnight, up to 5 weeks

  2. Change in Emotional Regulation - recall

    Participants complete a recognition phase. In this phase, 200 neutral and negative images are viewed. This set includes the 140 previously viewed images intermixed with 70 novel images (50% negative and 50% neutral). Participants are asked to assess arousal using the SAM (degree of emotional arousal experienced while processing the picture by pressing one of nine response buttons (ranging from 1 = very low to 9 = very high)), and to indicate whether or not they recognize pictures from the previous encoding session (''old'') or not (''new'') by pressing one of two response buttons.

    Time frame: First overnight session to second overnight, up to 5 weeks

  3. Change in Slow-wave Activity (SWA)

    Measured by overnight high-density EEG

    Time frame: First overnight session to second overnight, up to 5 weeks

Secondary outcomes

  1. Change in Positive and Negative Affect Schedule (PANAS)

    PANAS consists of 10 positive and 10 negative valence word items. Items are rated by the participant to indicate their assessment of how they are feeling about this item "right now" on a scale of 1(slightly) or not at all through 5 (extremely). 10 of of the items form a positive affect subscale, in which a higher score indicates increased positive affect, with a subscale range of 10 to 50. 10 of the items form a negative affect subscale, in which a higher score indicates more negative affect, with a subscale range of 10 to 50.

    Time frame: First week at-home recordings to second week, up to 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Oct 2028, 50 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 50 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Jul 16, 2024
Primary completionEst.
Oct 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341413
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Jul 16, 2024
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Sara Heyn, JD, PhD
Contact
sheyn@wisc.edu
303-296-2116
Stephanie Jones, MD, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion